The effect of rifampin on pharmacokinetics of digoxin in humans (Greiner et al., 1999)
| Digoxin 1 mg p.o. | Digoxin 1 mg i.v. | |||
|---|---|---|---|---|
| Control | With Rifampina | Control | With Rifampina | |
| AUC(0-144h) (ng/h/ml) | 54.8 ± 11.6 | 38.2 ± 12.4* | 87.3 ± 8.3 | 74.5 ± 10.5* |
| Bioavailability (%) | 63 ± 11 | 44 ± 14* | ||
| Tmax (min) | 42 ± 12 | 52 ± 18* | ||
| Cmax (ng/ml) | 5.4 ± 1.9 | 2.6 ± 0.7** | 24.7 ± 5.2 | 20.9 ± 1.8 |
| Renal clearance (ml/min) | 159 ± 30 | 159 ± 38 | 151 ± 25 | 147 ± 18 |
| Nonrenal clearance (ml/min) | 17 ± 17 | 54 ± 29** | ||
| T1/2 (h) | 56 ± 13 | 54 ± 13 | 58 ± 12 | 53 ± 11 |
*P < 0.05; ** P < 0.01.
↵ a 600 mg/day of rifampin were administered to healthy volunteers for 10 days.